Baricitinib
Kinase inhibitor
Product Specifications
Background
Baricitinib acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2, therby reducing cytokine release and suppressing the innate and adaptive immune systems. It was recently shown to significantly improve COVID-19 symptoms in a preliminary human trial, presumably through suppression of the cytokine release syndrome (“cytokine storm”) induced by SARS-CoV-2 infection.
Product Name Alternative
1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile, INCB028050, LY3009105
UNSPSC
41116105
Source
Synthetic
Purity
>98% (HPLC); NMR (Conforms)
Weight
0.005
Format
White to off-white powder
Solubility
May be dissolved in DMSO (30 mg/ml); or DMF (50 mg/ml)
Molecular Formula
C16H17N7O2S
Molecular Weight
371.4
Precautions
Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
References & Citations
1."Summary of opinion for Olumiant" (PDF). European Medicines Agency (EMA). 15 December 2016. 2. Cantini F., et al. (2020) J. Infect. DOI: 10.1016/j.jinf.2020.04.017
CAS Number
1187594-09-7
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
